Global Porcine Vaccines Market, By Indication (Swine Fever, Porcine Parvovirus, Aujeszky's Disease, Swine Colibacillosis, Porcine Pneumonia, Porcine Pleropneumoniae, Others), Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines), Product Type (Improvac, Suvaxyn, Circumvent, Circovac, Others), Route of Administration (Intravenous, Intramuscular, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
Porcine Vaccines Market Analysis and Size
The increase in the incidence of diseases in swine globally is one of the primary factors boosting market growth. In the U.S., advancements in vaccine development involve the development of live vector vaccines, nucleic acid-mediated vaccines, non-replicating recombinant antigen vaccines, and live-gene-deleted vaccines. Several companies operating in the poultry vaccine market primarily focused on developing new technological solutions to boost their position.
Data Bridge Market Research analyses that the porcine vaccines market, which was USD 1.6 billion in 2022, would rise to USD 2.40 billion by 2030 and is expected to undergo a CAGR of 5.20% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Porcine Vaccines Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Swine Fever, Porcine Parvovirus, Aujeszky's Disease, Swine Colibacillosis, Porcine Pneumonia, Porcine Pleropneumoniae, Others), Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines), Product Type (Improvac, Suvaxyn, Circumvent, Circovac, Others), Route of Administration (Intravenous, Intramuscular, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Boehringer Ingelheim International GmbH. (Germany), FORMOSA BIOMEDICAL INC. (Taiwan), Zoetis (U.S.), Dechra Pharmaceuticals PLC (U.K.), Hester Biosciences Limited. (India), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Elanco (U.S.), Phibro Animal Health Corporation (U.S.), HIPRA, S.A (Spain), Bimeda, Inc (Ireland), Ceva (France), ARKO Laboratories (U.S.)
|
|
Market Opportunities
|
|
Market Definition
The porcine vaccine is an administrative and clinical drug that helps improve swine health. These vaccines are known to protect from serious viruses, pathogens, and bacteria. Swine influenza, respiratory syndrome, diarrhea, and respiratory syndrome have been greatly minimized from spreading in an endemic manner because of these vaccines. It is widely used in several diseases, such as avian influenza and infectious bronchitis, requiring dosage form in liquid, freeze-dried, and duct.
Global Porcine Vaccines Market Dynamics
Drivers
- Increasing Research Activities Associated with Porcine vaccines
The increasing R&D activities by the major market players for developing novel porcine vaccines to treat diseases and increasing product approvals are anticipated to aid in the positive growth of the studied market during the forecast period. For instance, the Classical Swine Fever (CSF) vaccine was launched under the Raksha Class by Indian Immunologicals Limited (IIL) brand name in 2021. Therefore, increasing product launches expected market growth over the forecast period. This factor leads to the growth of the market.
- Increasing Healthcare Expenditure from Organizations
There have been rising healthcare expenditures that have led to market growth. For instance, in 2021, as per the Congress Budget Office report, the pharmaceutical industry spent USD 83 billion on research and development. These costs were paid for numerous activities, which include discovering and testing new drugs, developing incremental innovations such as product extensions, and conducting clinical trials for safety monitoring or marketing purposes. Thus, this factor help in the market growth.
Opportunities
- Increasing Awareness of Vaccination Services in Universities
Veterinary universities primarily deliver vaccination services to assist small-scale porcine farmers with disease control measures. For instance, the College of Veterinary Medicine at the University of Illinois created a website to offer information and resources to pork producers for their biosecurity program on farms. Also, training farm employees is creating a biosecurity plan that is necessary to prevent high-risk pathogens from entering and affecting swine farms. Thus, this factor boosts market growth.
- Increasing Usage of Inactivated Vaccines
Recently, inactivated vaccines are in use, leading to market growth. This is due to its easy availability, low cost, and stability advantages over live-attenuated vaccines. They reduce the risk of virulence reversion after vaccination, as it helps prevent pathogens' replication process. Furthermore, it provides swine with better immunization with a rapid cell-mediated immune response. Thus, this factor serves as a major factor that increases market growth.
Restraints/Challenges
- Side-Effects of Porcine Vaccines
Numerous effects are associated with porcine vaccine products. Local effects such as discomfort and local swelling at the vaccination site, reduced appetite and activity, sneezing, mild fever, a snotty nose, and mild coughing. Thus, this factor impedes market growth.
This porcine vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the porcine vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2022, Merck Animal Health received license approval in the U.S. from the Department of Agriculture (USDA) for its Circumvent CML vaccine. Merck passed a press release that claims Circumvent CML is the first-ready-to-use, single-dose vaccine which is effective against disease caused by Porcine Circovirus Types 2a and 2d.
Global Porcine Vaccines Market Scope
The porcine vaccines market is segmented on the basis of indication, technology, product type, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Swine Fever
- Porcine Parvovirus
- Aujeszky's Disease
- Swine Colibacillosis
- Porcine Pneumonia
- Porcine Pleropneumoniae
- Others
Technology
- Live Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Other Vaccines
Product Type
- Improvac
- Suvaxyn
- Circumvent
- Circovac
- Others
Route of Administration
- Intravenous
- Intramuscular
- Others
End Use
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Other
Porcine Vaccines Market Regional Analysis/Insights
The porcine vaccines market is analyzed and market size insights and trends are provided by indication, technology, product type, route of administration, end users and distribution channel as referenced above.
The countries covered in the porcine vaccines market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to grow during the forecast period of the porcine vaccines market because of the well-established veterinary healthcare infrastructure in the region. Also, the wide presence of top porcine production countries, such as China, and a large meat-consuming population, are boosting the market growth.
North America dominates the market in the forecast period due to increased infectious diseases within the region, such as classical swine fever (CSF). The increasing presence of a well-established veterinary healthcare infrastructure, growing demand for animal protein, and highly organized farming structure are anticipated to boost market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The porcine vaccines market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for porcine vaccines market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the porcine vaccines market. The data is available for historic period 2011-2021.
Competitive Landscape and Porcine Vaccines Market Share Analysis
The porcine vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to porcine vaccines market.
Some of the major players operating in the porcine vaccines market are:
- Boehringer Ingelheim International GmbH. (Germany)
- FORMOSA BIOMEDICAL INC.(Taiwan)
- Zoetis (U.S.)
- Dechra Pharmaceuticals PLC (U.K.)
- Hester Biosciences Limited. (India)
- Merck & Co., Inc. (U.S)
- Novartis AG (Switzerland)
- Elanco (U.S.)
- Phibro Animal Health Corporation (U.S.)
- HIPRA, S.A (Spain)
- Bimeda, Inc (Ireland)
- Ceva (France)
- ARKO Laboratories (U.S.)
SKU-